Investment Value in Healthcare Ventures: The Legal Dimensions of argenx's USD 1.15 Billion Deal

Investment Value in Healthcare Ventures: The Legal Dimensions of argenx's USD 1.15 Billion Deal

The agreement by biotechnology company argenx to acquire Unnatural Products illustrates the extent to which scientific research in the healthcare sector is capable of attracting investment. In realizing that potential, however, intellectual property rights, research collaborations and regulatory risks play a decisive role.

argenx, which develops medicines for immune-mediated diseases, announced on 9 November 2026 that it had entered into an agreement to acquire the remaining shares of US-based Unnatural Products ("UNP"). The transaction provides for an upfront payment of USD 550 million and up to USD 595 million in additional payments contingent upon the achievement of specified development and regulatory milestones, bringing the potential aggregate consideration to USD 1.145 billion. The acquisition has not yet closed; subject to customary closing conditions, it is expected to be completed by the end of the year. The transaction demonstrates that, in healthcare ventures, the conversion of a scientific idea into investment value depends as much on the soundness of its legal framework as on the quality of the underlying technology. [1][2]

From Scientific Research to Investment Value

Unnatural Products was founded in 2017 by Cameron Pye and Joshua Schwochert following their university research. Launched by the two researchers in a garage in Santa Cruz, the venture subsequently focused on a technology enabling the discovery of new drug candidates. UNP works on a class of molecules known as macrocyclic peptides, an approach aimed at exploring new therapeutic options against certain biological targets that are difficult to address using existing methods. The company's technology combines laboratory work with computational methods and machine learning. [3] In subsequent years, the company entered into research collaborations with pharmaceutical and biotechnology companies including Merck, BridgeBio, argenx and Novartis. In March 2026, it completed a USD 45 million Series B financing round led by The Venture Collective, in which argenx also participated. [4]

What is notable in UNP's case is that investor interest was directed not merely at a particular drug candidate, but at a technology capable of being deployed across multiple research programs. For healthcare and biotechnology ventures, this points to significant potential: scientific know-how, technologies enabling research into new treatment methods, and development partnerships can attract investment even at stages before any product has been made available to patients. The creation of investment value does not, however, mean that the research will achieve clinical success or that a therapy will obtain the requisite approvals. In biotechnology in particular, scientific uncertainty, lengthy development timelines and regulatory requirements remain.

Intellectual Property: Rights in the Venture's Technology

The conversion of scientific work developed at a university into a commercial venture raises significant intellectual property issues. The owner of an invention made by a researcher is not necessarily, in every case, the researcher. The institution at which the research was conducted, the agreements between the parties, the nature of the funding provided and the applicable legislation may all bear upon ownership.

In Türkiye, inventions made at higher education institutions are governed by Article 121 of Industrial Property Law No. 6769 and the related implementing regulation. These provisions set out procedures including the disclosure of the invention and the university's right to claim ownership of it. [5]

In the United States, the Bayh-Dole Act may be relevant to federally funded research. However, the Act neither applies to every academic invention nor automatically vests title in the university. [6] Accordingly, one of the threshold legal questions for a healthcare venture founded by researchers is whether there is clarity as to the rights under which it is entitled to use the technology it has developed.

This analysis is not limited to patents. Research methodologies, software, information qualifying as trade secrets and technologies acquired from third parties may also be material. UNP is known to have originated from academic research. Publicly available information does not, however, disclose the chain of title to all of the company's inventions or any related assignment agreements. Accordingly, no definitive conclusion can be reached as to the terms on which any particular patent was transferred from the university to the company.

Licensing and Ownership in Research Collaborations

Healthcare ventures may enter into research and license agreements with large pharmaceutical companies in order to advance their technologies. Such collaborations can help ventures expand their research capacity and access the resources required to develop new therapeutic candidates. At the same time, however, they define the rights of use in the technology concerned.

For example, the grant of an exclusive license to a particular technology under a research agreement may restrict the venture's ability to use the same technology with another partner. The ownership of new inventions arising from joint work, and which party will control the filing and prosecution of patent applications, are likewise among the matters that must be addressed in the agreements. UNP's relationships with Merck, Novartis and argenx are significant in this respect. The research agreement that UNP entered into with argenx in July 2025 granted argenx an exclusive option to develop and commercialize products directed at targets selected by argenx; the agreement also provided for an equity investment by argenx in UNP. [7]

It would, however, be inappropriate to speculate as to the undisclosed terms of these agreements. From an investor's perspective, what matters is not only the scientific merit of a venture's technology, but also the rights of use and contractual restrictions to which that technology is subject.

How Regulatory Risks Are Reflected in Investment Agreements

In investment transactions involving healthcare ventures, the stage of development of the technology and the regulatory framework to which it is subject are also of significance. In drug development in particular, laboratory research, clinical trials and marketing authorization constitute distinct phases. Even where early research results are promising, there can be no assurance that the same results will be achieved at later stages. These uncertainties may be reflected in the payment structure of investment and acquisition agreements.

The argenx–UNP agreement, under which up to USD 595 million in payments, in addition to the USD 550 million upfront consideration, are contingent upon specified development and regulatory milestones, is an example of this. The additional payments are conditional upon the satisfaction of the disclosed conditions. [1] Similarly, the obligations of a healthcare venture vary depending on the nature of the product it develops. A biotechnology company developing pharmaceuticals is not subject to the same legal requirements as a medical device manufacturer or a digital health venture that processes patients' health data. Accordingly, pre-investment reviews should address separately the product's intended use, its target markets, the required authorizations and the associated data processing activities.

The Importance of Legal Due Diligence in Investments in Healthcare Ventures

The matters that investors in health technology must assess extend beyond the company's financial position and the technology it has developed. In research-based ventures in particular, legal due diligence helps to establish whether the rights arising from scientific work vest in the company and whether those rights support its future development activities. In this context, the ownership of intellectual property rights, existing relationships with universities or research institutions, third-party licenses, rights in inventions arising from joint research and the applicable regulatory obligations come to the fore.

Exclusivity, change-of-control or assignment provisions in existing agreements may also affect new investment and acquisition transactions. It cannot be assumed, however, that such provisions are contained in every agreement; the assessment must be made on the basis of the specific contract.

For founders, systematically documenting the agreements entered into in the course of developing the technology can reduce uncertainty as to ownership in subsequent investment processes.

UNP's story shows that scientific research can attract substantial investment while contributing to the development of new treatment options in healthcare. Nevertheless, no amount of investment, in and of itself, guarantees the clinical outcome of the research or any benefit that may ultimately be delivered to patients.

The sustainability of investment value in healthcare ventures depends not only on scientific potential, but also on the legal protection of the technology developed, the proper structuring of research collaborations and the management of regulatory risks from the earliest stages.

Sources

1. argenx, argenx to Acquire Unnatural Products, Inc., Adding Peptide Discovery Engine to Broaden Immunology Capabilities, 9 November 2026. https://argenx.com/news/2026/press-release-3398049

2. U.S. Securities and Exchange Commission, argenx SE, Form 6-K, Exhibit 99.1: announcement regarding the acquisition, 9 November 2026. https://www.sec.gov/Archives/edgar/data/1697862/000110465926124060/tm2629301d2_ex99-1.htm

3. Unnatural Products, About Us. https://www.unnaturalproducts.com/about

4. Unnatural Products, Unnatural Products Raises $45 Million Series B Financing to Advance Macrocyclic Peptide Therapeutics, 16 March 2026. https://www.globenewswire.com/news-release/2026/03/16/3256110/0/en/Unnatural-Products-Raises-45-Million-Series-B-Financing-to-Advance-Macrocyclic-Peptide-Therapeutics.html

5. Industrial Property Law No. 6769, Article 121; Regulation on Employee Inventions, Inventions Made at Higher Education Institutions and Inventions Arising from Publicly Funded Projects, Official Gazette of the Republic of Türkiye, 29 September 2017, Issue No. 30195. https://www.resmigazete.gov.tr/eskiler/2017/09/20170929-6.htm

6. United States, Bayh-Dole Act, 35 U.S.C. §§ 200–212; Board of Trustees of Leland Stanford Junior University v. Roche Molecular Systems, Inc., 563 U.S. 776 (2011). https://uscode.house.gov/uscode/prelim@title35/part2/chapter18 ; https://www.law.cornell.edu/supremecourt/text/09-1159

7. Unnatural Products, Unnatural Products Announces Multi-Target Collaboration with argenx to Develop Oral Macrocyclic Peptide Therapeutics, 1 July 2025. https://www.globenewswire.com/news-release/2025/07/01/3108284/0/en/unnatural-products-announces-multi-target-collaboration-with-argenx-to-develop-oral-macrocyclic-peptide-therapeutics.html

Author

Erdem Aktürk